argenx Dividend
Dividend criteria checks 0/6
argenx does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$4.97 |
Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01argenx on target to file efgartigimod applications in Japan and Europe
Jan 08argenx and Zai Lab collaborate for Efgartigimod in Greater China
Jan 06Argenx inks $98M deal to secure accelared review status for efgartigimod
Nov 23argenx (ARGX) Investor Presentation - Slideshow
Nov 18Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ARGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARGX's dividend payments have been increasing.
Dividend Yield vs Market
argenx Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ARGX) | n/a |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.8% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (ARGX) | 0% |
Notable Dividend: Unable to evaluate ARGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ARGX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ARGX has not reported any payouts.